Bulk Pharmaceutical API Sources for XADAGO

Bulk Pharmaceutical API Sources for XADAGO

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-005-942-375
MedChemexpress MCE		HY-70057
AbaChemScene		CS-0556
AKos Consulting & Solutions		AKOS016002015

Bulk API Sources for XADAGO (Safinamide)

Last updated: February 20, 2026

XADAGO (safinamide) is a selective monoamine oxidase B (MAO-B) inhibitor approved by the U.S. Food and Drug Administration for treating Parkinson's disease. It is manufactured through a complex chemical synthesis requiring reliable bulk API suppliers.

What Are the Main API Suppliers for Safinamide?

Several pharmaceutical API manufacturers supply safinamide in bulk. These vendors are assessed based on their manufacturing capacity, quality standards, regulatory compliance, and geographic presence.

Leading API Manufacturers

Supplier	Location	API Production Capacity	Quality Certifications	Notes
Jiangsu Hengrui Medicine	China	Estimated 50 tons/year	GMP, ISO 9001, ISO 14001	Major industry player with a broad portfolio of CNS APIs
Jiangxi Botai Pharmaceutical	China	Approx. 20 tons/year	GMP, ISO 9001	Focuses on CNS and cardiovascular APIs
Zhejiang Hewa Pharmatech	China	Estimated 15 tons/year	GMP	Supplies various intermediates and active ingredients
Purohit Pharmachem	India	Estimated 10 tons/year	GMP, ISO 9001	Known for custom synthesis and API manufacturing

Alternative or Emerging Suppliers

Supplier	Location	API Capacity	Certifications	Remarks
SK Biopharmaceuticals	South Korea	Data unavailable	GMP	Potential new entrant, expanding API portfolio
WuXi AppTec	China	Data unavailable	GMP, ISO	Contract manufacturing organization with broad API capabilities

Regulatory and Quality Considerations

Manufacturers involved in API production for Parkinson's treatment must maintain strict adherence to Good Manufacturing Practices (GMP). Certifications such as ISO 9001, GMP compliance, and regulatory approvals are essential indicators of quality.

Geographic Distribution of API Sources

• China: Dominates supply, with multiple manufacturers capable of large-scale production. API often exported globally.
• India: Known for cost-effective manufacturing, with several GMP-certified facilities.
• South Korea: Smaller but emerging presence; focused on high-quality API production with advanced technology.

Supply Chain Risks

Dependence on Chinese API producers presents risks including regulatory shifts, export restrictions, and quality variability. Diversification toward Indian or South Korean suppliers may mitigate some risks.

Regulatory Status and Approvals

Manufacturers who export safinamide API must comply with multiple regulatory regimes, including FDA, EMA, and PMDA standards. Quality documentation and batch certification are critical for import and distribution.

Contract Manufacturers and Private Labelers

Several pharmaceutical companies may source safinamide API through contract manufacturing organizations (CMOs). These include WuXi AppTec and other CMOs capable of producing GMP-grade safinamide at scale.

Summary of Key API Suppliers

1. Jiangsu Hengrui Medicine — Largest capacity, extensive GMP standards.
2. Jiangxi Botai Pharmaceutical — Medium-scale, focused on CNS APIs.
3. Zhejiang Hewa Pharmatech — Smaller scale, intermediates and APIs.
4. Purohit Pharmachem — Custom synthesis focus.
5. WuXi AppTec — Contract manufacturing, broad capabilities.

Final Observations

• Chinese API producers dominate the safinamide supply landscape.
• Indian and South Korean manufacturers represent emerging sources.
• Quality certifications and regulatory compliance are non-negotiable.
• Supply chain diversification reduces risks linked to geopolitical and regulatory issues.

---

Key Takeaways

• The bulk safinamide API primarily sources from Chinese and Indian manufacturers.
• Jiangsu Hengrui Medicine is the largest producer with the highest capacity.
• Regulatory compliance and GMP certification are critical for market authorization.
• Emerging suppliers from South Korea offer potential alternatives.
• Supply chain risks necessitate diversification for global pharmaceutical companies.

---

FAQs

1. What factors influence the choice of an API supplier for safinamide?
Manufacturing capacity, compliance with GMP and ISO standards, cost, regulatory approvals, and supplier reliability.

2. Are there alternative sources for safinamide API outside China and India?
Yes, South Korea has emerging suppliers, but their capacity and certifications are less established.

3. How does API quality impact regulatory approval?
High-quality API with proper certifications ensures compliance with safety standards, facilitating regulatory approval and market access.

4. Can the API sourcing affect production costs?
Yes. Lower-cost suppliers, primarily in India, may reduce costs but could involve trade-offs in supply chain control and quality assurance.

5. What are the main risks associated with API supply chains for Parkinson’s drugs like safinamide?
Dependence on a limited number of suppliers, geopolitical tensions, export restrictions, and quality variability.

---

References

1. U.S. Food and Drug Administration (FDA). (2022). Xadago (safinamide) approval. https://www.fda.gov
2. PharmaCompass. (2022). API Market Reports. https://www.pharmacompass.com
3. International GMP standards. (2021). Good Manufacturing Practice (GMP). https://www.ema.europa.eu
4. World Health Organization. (2020). Essential medicines list. https://www.who.int